NKCFO LLC’s NeoGenomics NEO Stock Holding History

NKCFO LLC’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,100	Closed	-$140K	–	97
2021 Q2	$140K	Buy	+3,100	New	+$137K	0.05%	89

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

NKCFO LLC's NEO Position: Q3 2021 in Review

NKCFO LLC sold out of NeoGenomics (NEO) in Q3 2021, closing a stake of 3,100 shares — an estimated $140K sold.

NKCFO LLC first reported a position in NEO in Q2 2021 and held it in 1 quarter. The position peaked at $140K in Q2 2021. 324 funds tracked by Wall St. Rank hold NEO as of Q3 2021.

NKCFO LLC reported no remaining NeoGenomics position as of Q3 2021 after selling out during the quarter.
NKCFO LLC sold 3,100 NeoGenomics shares in Q3 2021, an estimated $140K.
NKCFO LLC first reported a position in NeoGenomics in Q2 2021 and held it in 1 quarter.
NKCFO LLC's NeoGenomics position peaked at $140K in Q2 2021.
324 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2021.

Based on NKCFO LLC's 13F filing for Q3 2021, filed 21 Oct 2021.